Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
1(25.0%)
Phase 3
1(25.0%)
4Total
Phase 2(2)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02840539Phase 2Completed

Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma

Role: collaborator

NCT03052933Phase 1Completed

Copanlisib and Gemcitabine in Relapsed/Refractory PTCL

Role: collaborator

NCT01448096Phase 2Completed

Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma

Role: collaborator

NCT03123718Phase 3Unknown

High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL

Role: collaborator

NCT02386813Completed

International Extranodal NK/T-cell Lymphoma Project

Role: collaborator

All 5 trials loaded